Almudena Mateu Puchades - JoVE Visualize

Showing results (21-30 of 30) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 30 results.

Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 12, 2023

Clinicopathological characteristics of cutaneous and mucocutaneous leishmaniasis in patients treated with TNF-α inhibitorsRodolfo David Palacios-Diaz, Antonio Sahuquillo-Torralba, Vicenç Rocamora-Durán, et al.

The Australasian Journal of Dermatology|September 9, 2025

Guselkumab for Psoriasis in Patients With Active or Prior Malignancy: A Multicentre Retrospective StudyFrancisco Javier Melgosa Ramos, Sergio Santos Alarcón, Almudena Mateu Puchades, et al.

Journal of the American Academy of Dermatology|March 16, 2019

A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patientsJosé-María Ortiz-Salvador, Martina Saneleuterio-Temporal, Jorge Magdaleno-Tapial, et al.

The Australasian Journal of Dermatology|December 5, 2025

Efficacy and Safety of Risankizumab in Psoriatic Patients With a History of Malignancy: Real-World Evidence From a Multicentre Spanish StudyJavier Mataix Díaz, Sergio Santos Alarcón, Isabel Belinchón Romero, et al.

Clinical and Experimental Dermatology|March 2, 2024

Efficacy of omalizumab for the treatment of bullous pemphigoid: Spanish multicentre real-world experienceÁlvaro Aguado Vázquez, Andrea Estébanez Corrales, F Javier Melgosa Ramos, et al.

Pigment Cell & Melanoma Research|May 27, 2023

Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort studySebastian Ochenduszko, Javier García Sanchez, María José Juan Fita, et al.

Actas Dermo-Sifiliograficas|January 2, 2026

Survival of Interleukin-17 and Interleukin-23 Inhibitors in Patients Previously Treated with a Tumor Necrosis Factor Inhibitor: Analysis of the Spanish Biobadaderm RegistryRaquel Rivera-Díaz, Alicia Quesada, Antonio Sahuquillo-Torralba, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV|August 25, 2023

Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis GroupSonsoles Berenguer-Ruiz, Mario Aparicio-Domínguez, Pedro Herranz-Pinto, et al.

International Journal of Dermatology|September 11, 2025

Tildrakizumab in Psoriatic Patients With Current or Past Malignancy: A Real-Life Cohort and Literature ReviewOfelia Baniandrés, Inmaculada Balaguer Franch, Eva Vilarrasa Rull, et al.

Actas Dermo-Sifiliograficas|May 23, 2026

Safety Profile of Systemic Therapy for the Management of Psoriasis in Patients With Diabetes Mellitus: Data From the BIOBADADERM Prospective CohortJuan José Lluch-Galcerá, José Manuel Carrascosa, Alicia González-Quesada, et al.

Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 30 results.

Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 12, 2023

Clinicopathological characteristics of cutaneous and mucocutaneous leishmaniasis in patients treated with TNF-α inhibitorsRodolfo David Palacios-Diaz, Antonio Sahuquillo-Torralba, Vicenç Rocamora-Durán, et al.

The Australasian Journal of Dermatology|September 9, 2025

Guselkumab for Psoriasis in Patients With Active or Prior Malignancy: A Multicentre Retrospective StudyFrancisco Javier Melgosa Ramos, Sergio Santos Alarcón, Almudena Mateu Puchades, et al.

Journal of the American Academy of Dermatology|March 16, 2019

A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patientsJosé-María Ortiz-Salvador, Martina Saneleuterio-Temporal, Jorge Magdaleno-Tapial, et al.

The Australasian Journal of Dermatology|December 5, 2025

Efficacy and Safety of Risankizumab in Psoriatic Patients With a History of Malignancy: Real-World Evidence From a Multicentre Spanish StudyJavier Mataix Díaz, Sergio Santos Alarcón, Isabel Belinchón Romero, et al.

Clinical and Experimental Dermatology|March 2, 2024

Efficacy of omalizumab for the treatment of bullous pemphigoid: Spanish multicentre real-world experienceÁlvaro Aguado Vázquez, Andrea Estébanez Corrales, F Javier Melgosa Ramos, et al.

Pigment Cell & Melanoma Research|May 27, 2023

Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort studySebastian Ochenduszko, Javier García Sanchez, María José Juan Fita, et al.

Actas Dermo-Sifiliograficas|January 2, 2026

Survival of Interleukin-17 and Interleukin-23 Inhibitors in Patients Previously Treated with a Tumor Necrosis Factor Inhibitor: Analysis of the Spanish Biobadaderm RegistryRaquel Rivera-Díaz, Alicia Quesada, Antonio Sahuquillo-Torralba, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV|August 25, 2023

Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis GroupSonsoles Berenguer-Ruiz, Mario Aparicio-Domínguez, Pedro Herranz-Pinto, et al.

International Journal of Dermatology|September 11, 2025

Tildrakizumab in Psoriatic Patients With Current or Past Malignancy: A Real-Life Cohort and Literature ReviewOfelia Baniandrés, Inmaculada Balaguer Franch, Eva Vilarrasa Rull, et al.

Actas Dermo-Sifiliograficas|May 23, 2026

Safety Profile of Systemic Therapy for the Management of Psoriasis in Patients With Diabetes Mellitus: Data From the BIOBADADERM Prospective CohortJuan José Lluch-Galcerá, José Manuel Carrascosa, Alicia González-Quesada, et al.

Pageof 3